Body Weight Changes
Conditions
Keywords
Overweight, Obesity, L-Carnitine, Body weight, Body fat percentage
Brief summary
The L-carnitine has demonstrated effects in the treatment of obesity mainly promoting the fat degradation during exercise.
Detailed description
A randomized, double-blind, placebo-controlled clinical trial will be carry out in 24 woman with body mass index ≥ 25 to 29.9 kg/m2. The patients will receive 1.5 g of L-Carnitine deluded in 250 ml of water or placebo before crossfit training, 5 times a week for 8 weeks. Before and after intervention the investigators evaluate: The body composition (body fat, lean body mass), arm muscle circumference, waist circumference, body weight and body mass index.
Interventions
DRUGL-Carnitine
L-Carnitine oral solution 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
DIETARY_SUPPLEMENTSucralose
Sucralose 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
Sponsors
University of Guadalajara
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Volunteers who practice crossfit regularly (who have 3 months prior to the beginning of the study practicing crossfit). * Volunteers with a body mass index equal to or greater than 25 Kg/m2. * Volunteers who do not have allergies to L-Carnitine or any of its components. * Informed consent signed * Women with a recommendation of nutrition two weeks prior to the start of the study. * Body weight stable the last 3 months.
Exclusion criteria
* Volunteers with pathologies such as diabetes, hypertension, metabolic syndrome and allergies. * Women with confirmed or suspected pregnancy. * Women under lactation and/or puerperium. * Hypersensibilility to L-Carnitine or Sucralose. * Kown of renal, hepatic or thyroid deseased. * Current or previous treatment diet (3 months before inclusion to the study). * Current pharmacological treatment for loose body weight or 3 months before inclusion to the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Body Fat | 8 weeks | Calulated by Durnin formula. Results are reported in percentage and kg |
| Lean body mass | 8 weeks | Calulated by Durnin formula. Results are reported in percentage and kg |
| Body Weight | 8 weeks | Subject go up onto the scale and stand still over the center of the scale with body weight evenly distributed between both feet. Omron hbf-514c an digital scale and results are reported in kg with a decimal. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Arm muscle circumference | 8 weeks | The right arm measure to the nearest centimeter with a measuring tape. Then, triceps skinfold thickness, an established measure of fat stores, measure to the nearest millimeter in the right arm using a skinfold caliper |
| Waist circumference | 8 weeks | Flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters. Waist circumference was measured with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters. Waist circumference was measured with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters. |
| Body Mass Index | 8 weeks | Body mass divided by the square of the body height, and reported in units of kg/m2. |
Countries
Mexico
Contacts
Primary ContactDiana M Hernández, PhD
Backup ContactTonatiuh González, PhD
Outcome results
None listed